#United States #Austin #PDX Models #Altogen Labs #CDX Models

Introduction

In the evolving landscape of preclinical cancer research, the meticulous selection and standardization of xenograft models play a vital role in the effectiveness and reliability of studies aimed at cancer treatment. Altogen Labs has spearheaded this initiative by publishing a comprehensive framework in the Journal of Visualized Experiments (JoVE), which outlines the various xenograft models available and their optimal applications in preclinical oncology. This framework is designed to guide researchers in their model selection to bridge the gap between early efficacy assessments and safety evaluations crucial for Investigational New Drug (IND) applications.

Understanding Xenograft Models

Xenograft models, specifically those derived from patient tumors, have become increasingly popular due to their capacity to mirror human cancer biology more accurately than traditional rodent models. This research integrates various types of xenograft models—CDX (Cell Line-Derived Xenografts), PDX (Patient-Derived Xenografts), humanized, and organoid-derived models—each serving distinct roles at different development stages. CDX models are particularly notable for their rapid turnaround, yielding results in just 5 to 7 weeks, making them the go-to option for early efficacy evaluations.

The Role of CDX and PDX Models

The framework emphasizes the comparative advantages of CDX and PDX models. While CDX models deliver swift results with robust data on dose-response, pharmacokinetics, and tolerability, PDX models preserve the tumor’s original histological and genomic characteristics. This preservation holds significant implications for biomarker development and resistance modeling, which take place over longer periods, typically between 16 to 32 weeks. Researchers tackling the intricacies of tumor heterogeneity and treatment resistance will find PDX models especially beneficial.

Advancements with Humanized Platforms

Moreover, the emergence of humanized models represents a significant leap in immuno-oncology research. These platforms can effectively evaluate checkpoint inhibitors, bispecific T-cell engagers, and CAR-T therapies, which are challenging to assess in traditional immunodeficient animals. By reconstituting T-cells in these models, researchers can better simulate human immune responses, thus yielding insights into treatment efficacy under more realistic conditions.

Organoid-Derived Models

Completing the spectrum of available models, organoid-derived xenografts bridge the divide between ex vivo and in vivo studies. With a commendable capability for reducing tissue requirements and quickening validation processes—with timelines of 8 to 16 weeks—these models facilitate research especially where obtaining patient material poses challenges.

Importance of Standardization

The impact of model selection is amplified by the need for standardization across research institutions. The framework put forth includes four pivotal recommendations: PDX-MI, MISHUM, OBSERVE, and the NCI PDXNet guiding principles, aligned with ARRIVE 2.0 guidelines. This standardized approach ensures that findings are applicable across varied settings, which is essential for enhancing the translational value of preclinical studies. Despite the uneven adoption of these standards in the industry, Altogen Labs is committed to implementing high-quality assurance protocols throughout its xenograft research pipeline.

Conclusion

Altogen Labs stands at the forefront of preclinical cancer research by incorporating these comprehensive standards into their xenograft portfolio, from the initiation of CDX efficacy studies through more complex humanized and organoid-derived evaluations. The published framework represents a significant leap toward more cohesive and reliable preclinical research practices, ultimately aiding in the advancement of oncology drug development strategies.

For more detailed information, you can access the full publication entitled "Standardized Xenograft Models for Preclinical Cancer Research" available at jove.com/t/71892.

About Altogen Labs

Headquartered in Austin, Texas, Altogen Labs is a contract research organization specializing in preclinical studies, particularly xenograft efficacy, pharmacology, toxicity, and IND-enabling research in oncology. Their extensive array of platforms includes various types of xenograft models catered to major tumor types, empowering researchers with the tools needed to innovate in cancer treatment.